SCHEMBL1315299

SCHEMBL1315299

CCOc1ccc(N)c(C(=O)OC)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 1/20 0.43
NPSR1 Q6W5P4 1/20 0.41
MAPT P10636 3/20 0.41
ALDH1A1 P00352 6/20 0.40
HSD17B10 Q99714 5/20 0.40
KDM4E B2RXH2 5/20 0.40
HPGD P15428 3/20 0.40
GAA P10253 3/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
GCK P35557 1/20 0.38
CFTR P13569 2/20 0.38
RECQL P46063 1/20 0.37
GLA P06280 1/20 0.37
PKM P14618 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
NPC1 O15118 1/20 0.36
USP2 O75604 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1318082 0.84 MAPT (0.50) MAPK8MAPTALDH1A1HSD17B10KDM4E
SCHEMBL4257399 0.83 NPSR1 (0.47) NPSR1MAPTALDH1A1HSD17B10KDM4E
SCHEMBL31663021 0.83 NPSR1 (0.47) NPSR1MAPTALDH1A1HSD17B10KDM4E
SCHEMBL12736555 0.78 TDP1 (0.43) MAPK8MAPTALDH1A1HSD17B10KDM4E
SCHEMBL1312986 0.78 MAOA (0.50) MAPK8MAPTALDH1A1KMT2ASMN1; SMN2
SCHEMBL22140361 0.76 ALDH1A1 (0.46) MAPTALDH1A1HSD17B10KDM4EHPGD
SCHEMBL262928 0.75 GRM5 (0.54) NPSR1MAPTALDH1A1HSD17B10KDM4E
SCHEMBL30775059 0.75 GRM5 (0.54) NPSR1MAPTALDH1A1HSD17B10KDM4E
SCHEMBL1316697 0.75 NQO2 (0.42) NPSR1ALDH1A1HSD17B10KDM4EGAA
SCHEMBL7846688 0.74 HTR1A (0.49) MAPTKDM4EHPGDSMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2375899-B1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF IN THE TREATMENT OF DIABETES ARRAY BIOPHARMA INC (US) 2015-02-25 EP disclosed
EP-2375899-B1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF IN THE TREATMENT OF DIABETES ARRAY BIOPHARMA INC (US) 2015-02-25 EP disclosed
US-8809538-B2 Piperidine-containing compounds and use thereof ARRAY BIOPHARMA INC. (US) 2014-08-19 US disclosed
US-8809538-B2 Piperidine-containing compounds and use thereof ARRAY BIOPHARMA INC. (US) 2014-08-19 US disclosed
US-20110275608-A1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF ARRAY BIOPHARMA INC. (US) 2011-11-10 US disclosed
EP-2375899-A1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF Array Biopharma, Inc. (US) 2011-10-19 EP disclosed
WO-2010080864-A1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF ARRAY BIOPHARMA INC. (US) 2010-07-15 WO disclosed
WO-2010080864-A1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF ARRAY BIOPHARMA INC. (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275608-A1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF NOS1, NOS2, ASS1 MAPK8 3189/4885NPSR1 183/4885MAPT 2109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.